A new approach to reversing tissue aging

Latest articles

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

New webinar will explore the opportunity of ovarian longevity

What does delaying menopause mean in terms of investment activity, societal change and the technologies that will reshape the lives of multiple millions of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

Click the globe for translations.

Exploring Revel’s enzyme-based approach to breaking down crosslinks and targeting tissue aging.

Last year, a startup called Revel Pharmaceuticals emerged from the labs at Yale and revealed it was working on drugs targeting collagen crosslinks, with the aim of restoring tissue function and repairing the body. The company is developing therapeutic enzymes that break down the links between advanced glycation end-products (AGEs) in order to “repair the molecular damage that accumulates with aging.”

Longevity.Technology: Revel is focused on technology that can cleave damaging crosslinks and potentially reverse the age-related stiffening of tissues such as blood vessels, skin, and beyond. This stiffening is implicated in a range of conditions, from rising systolic blood pressure and skin aging, to kidney and brain damage. We caught up with the company’s co-founder and CEO Aaron Cravens to find out more about the company’s origins and where it stands today.

The history of Revel’s approach extends back to the 1990s and a company called Alteon, which developed small molecule therapies to break down AGE crosslinks and release the tissue stiffness that occurs with aging.

“The problem with Alteon’s drugs was that they were small molecules, which you can’t design to be terribly specific,” says Cravens. “In contrast, antibodies and enzymes can be highly targeted a degree of control you just don’t have with small molecules. There was initially a lot of excitement around the potential of these small molecule breakers, with players like Genentech getting involved, but unfortunately for a few different reasons they didn’t work out in the clinic.”

A new approach to reversing tissue aging
Revel co-founders Aaron Cravens and Nicholas DeLateur.

Enzymes vs small molecules

The formation of Revel, says Cravens, is a reimagination and expansion of targeting AGE crosslinks using enzymes rather than small molecules as the therapeutic.

“Enzymes are biologics, so we can be very precise as we make modifications to repair damaged proteins and break up crosslinks.”

Biotech entrepreneur Cravens had been interested in the aging field since the early 2000s, and the idea of breaking down collagen crosslinks to reverse aging resonated with his understanding of the stochastic nature of aging.

“When I looked around the aging space in 2019, I didn’t really see anything tangible forming in this space, so I decided to do it myself,” he says, explaining that he approached Yale Professors David Spiegel and Jason Crawford, who were working at the forefront of the technology – and so Revel came into being.

Cellular vs structural aging

While many companies in the aging field are focused on aspects of cellular aging, Cravens believes that Revel sets itself apart by instead focusing on aspects of structural aging.

“We’re quite unique right now, in the aging space – not many companies are focused on the structural, protein side of aging,” he says. “If you look at the literature and clinical data, it’s very clear that damage and crosslinking of collagen and other proteins is a significant contributor to aging. As the structure of the extracellular matrix surrounding cells becomes crosslinked and degraded, proteins begin to aggregate and lose functionality, tissues become stiffer, and the immune system becomes activated leading to low level inflammation.”

With its enzymatic approach, Revel is taking a new therapeutic modality to reach some well established targets, such as glucosepane, as well as other toxic protein modifications beyond just AGEs.

“We’re looking at the same targets that have been of interest for a long time, but no one’s had a good way to correct or repair them,” says Cravens. “We started out looking at glucosepane, the predominant crosslink in aging human tissue, but there are many other important aging crosslinks and damage products to which we’ve expanded our scope.”

A new approach to reversing tissue aging

Building a suite of enzymes

Having identified several lead candidates, Cravens says that Revel is now at the optimisation stage.

“Our work has led us to five or six interesting targets, which also serves to de-risk our pipeline, so all of our eggs aren’t in one basket. What we have now is a suite of enzymes targeting a suite of different damage products.”

Revel is preparing to move therapeutic enzymes into pilot studies in animal models and human cadaver tissue from biobanks.

“If we have 80 year old tissue that comes from a biobank, then the gold standard is really to show that, when we add our enzymes to that very old tissue, we can repair these modifications and correct the damage,” says Cravens. “Once that critical milestone is met for each enzyme, we will immediately push into animal studies and eventually clinical testing.”

While the company is keeping its lips sealed on specific clinical targets at this point, Cravens says that they hope to have a candidate in Phase 1 trials sometime in 2024.

Having previously raised an undisclosed Seed funding round from investors including KIZOO and Oculus co-founder Michael Antonov, the company is currently in the process of closing another round of funding, which Cravens says is already oversubscribed.

“We’re going to add a little bit more fuel to the fire over the next year or so. We have expanded the scope of biology, but we want to go much further into therapeutic development before we really unveil what we’ve been working on.”

 

Images from Revel Pharma.

 

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Buck Institute awarded $12.7m to join senescence network

NIH award to join SenNet, the Cellular Senescence Network, will enable Buck scientists to identify and characterise senescent cells – recognised as a driver...

Deep learning platform seeks near-term indications of age-related diseases

Arrive co-founder talks combining aging cell biology, drug screening and deep learning technology in the quest to discover novel antiaging targets. Silicon Valley and Singapore-based...

Ovarian aging – your questions answered

Ovarian longevity and the significance of ovarian aging is poorly understood – our video aims to change that. Join our Scientific Editor Daragh Campbell as...

Learning lessons from clinical trial failure

Metabesity 2021: Joan Mannick talks longevity scientific breakthroughs, healthspan endpoints, her new role at Life Biosciences, and what can be learned from resTORbio’s clinical...

Ovarian aging – what women aren’t told about their health

Ovaries set the pace for aging and changing that pace could be the key to improving fertility, healthspan and lifespan. Words like fertility, menstruation, menopause,...